News & Updates

Treatment delays do not necessarily contribute to cancer-specific survival (CSS) or locoregional recurrence (LRR) in patients with oropharynx carcinoma, reveals a study. However, time on treatment (TOT) of 1 to 3 days is associated with lower CSS.

Lenvatinib + pembrolizumab combination regimen improves progression-free survival (PFS) compared with sunitinib in a subset of East Asian patients with advanced renal cell carcinoma (aRCC), a finding that was similar to that of the global population of the CLEAR* trial, according to a subanalysis presented at ASCO GU 2022.

Asian and Hispanic oncologists, as well as female oncologists treating genitourinary malignancies, receive lower patient satisfaction scores (PSS), according to a study.

Salvage chemotherapy is preferable over surgery in patients with alpha-fetoprotein (AFP) >30 µg/l and human chorionic gonadotropin (HCG) ≥20 mIU/ml after first-line chemotherapy, suggests a study.

Eleven different malignancies seem to be correlate with metabolic syndrome (MS), as well as with the presence of MS components, reports a recent study.

Neoadjuvant chemotherapy may lead to worse overall survival in women who had undergone mastectomy and immediate breast reconstruction, a recent study has found.